European Pharmaceutical Review

JUNE 27, 2022

The European Commission (EC) has launched the Healthier Together: EU Non-communicable diseases (NCDs) initiative to support EU Member States in reducing the burden of NCDs by addressing the leading causes of avoidable premature death in Europe and improving citizens’ health and well-being. Europe’s Healthier Together initiative.

Medicine 93

Medicine Healthcare Healthcare Government 93

European Pharmaceutical Review

NOVEMBER 29, 2022

National Institute for Health and Care Research (NIHR)’s Clinical Research Network. It will also involve experts in infectious diseases and virology who will monitor the flu virus to see if it becomes resistant to the anti-viral drugs tested in the trial.

Medicine 98

Medicine Recruitment Consulting Healthcare 98

European Pharmaceutical Review

JANUARY 19, 2024

According to GlobalData, with demonstrated efficacy against carbapenem-resistant Acinetobacter Baumanni (CRAB), Roche’s zosurabalpin “has the potential to treat lethal hospital infection,” Anaelle Tannen, Infectious Disease Analyst at GlobalData explained. An example is Fetroja (cefiderocol sulfate tosylate).

Manufacturing 92

Manufacturing Medicine Leads Pharmaceutical 92

European Pharmaceutical Review

MARCH 26, 2024

“We are excited to announce our fourth infectious disease vaccine programme with positive Phase III data,” stated Stéphane Bancel, Chief Executive Officer of Moderna. These findings were based on data comparing the treatment to mRNA-1273.222 (Spikevax ® ), Moderna’s licensed vaccine for the condition.

Safety 93

Safety Leads Patients Pharmaceutical 93

World of DTC Marketing

OCTOBER 6, 2021

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, also provided Emory with more than $19 million in additional grants. originally developed it to treat other viral diseases. million for NIH-funded clinical trials. million for NIH-funded clinical trials.

Food and Drug Administration 198

Food and Drug Administration Government Medicine Food 198

Pharmaceutical Commerce

FEBRUARY 7, 2023

The new $43M plasmid manufacturing facility will support both clinical and commercial production in the cancer and infectious disease spaces.

Manufacturing 52

Manufacturing 52

European Pharmaceutical Review

APRIL 28, 2023

The initiative will help to improve clinical decision-making regarding antimicrobial use and also inform practices and guidelines for prescribers, users and policymakers. Researchers will work to build knowledge in optimal antibiotics use, improved access to effective treatment and better prevention and treatment of bacterial infections.

Networking 92

Networking Medicine Leads Pharmaceutical 92

pharmaphorum

JANUARY 6, 2023

The cancer immunotherapies will mainly be provided in the context of clinical trials over the alliance, which extends out to 2030, but also covers supply of commercial therapies if approved in the interim. It will also cover some infectious disease targets. ” Image via @BioNTech_Group twitter.

Manufacturing 105

Manufacturing Patients Leads 105

Pharmaceutical Technology

JUNE 24, 2022

GlaxoSmithKline (GSK) has announced plans to invest $1.2bn (£1bn) over a decade to expedite research and development (R&D) for infectious diseases in lower-income countries. These ailments are said to account for over 60% of the disease burden in several lower-income countries.

Pharmaceutical 59

Pharmaceutical Medicine Healthcare Healthcare 59

European Pharmaceutical Review

JULY 7, 2022

” Since September 2021, Dr Hughes has been Senior Vice President of Clinical Development and Translational Medicine at Vertex Pharmaceuticals, based in Boston. .” ” Since September 2021, Dr Hughes has been Senior Vice President of Clinical Development and Translational Medicine at Vertex Pharmaceuticals, based in Boston.

Medical 90

Medical Medicine Pharmaceutical Training 90

Pharmaceutical Technology

APRIL 17, 2023

Clinical-stage biotechnology company Smart Immune has secured $5m in equity investment from the Bill & Melinda Gates Foundation for expediting the development of its thymus-empowered ProTcell platform for the treatment of cancer and infectious diseases. SMART 101 is produced from healthy donor-mobilised peripheral blood.

Patients 52

Patients 52

Pharmaceutical Technology

MAY 30, 2023

The formulation is intended for indications, including systemic sclerosis, graft versus host disease, systemic lupus erythematosus 151, central nervous system inflammatory diseases associated with multiple sclerosis and infectious diseases linked to Covid-19.

Recruitment 52

Recruitment FDA Medical Pharmaceutical 52

pharmaphorum

JULY 7, 2022

In the second of a three-part series, Ben Hargreaves looks at the importance of early-stage research into various emerging infectious disease threats and how it saved precious time in the work to develop a working vaccine during the current pandemic. Research defence.

Government 82

Government 82

pharmaphorum

NOVEMBER 20, 2022

COVID-19 set new expectations for how quickly R&D can move; the Coalition for Epidemic Preparedness Innovations (CEPI) has since established a 100 Days Mission for responding to the next Disease X, but what needs to happen for this to become a reality? New hurdles from COVID-19 vaccine development.

Recruitment 80

Recruitment Government Consulting Management 80

European Pharmaceutical Review

DECEMBER 18, 2023

Collectively, these diseases cause more than 2.5 The only available TB vaccine does not prevent lung disease in adolescents and adults, while influenza vaccines have limited efficacy and only offer short-term protection. million deaths per year, according to the Novo Nordisk Foundation. There is currently no licensed GAS vaccine.

Pharmaceutical 94

Pharmaceutical 94

European Pharmaceutical Review

JULY 13, 2022

Afrigen Biologics and the US National Institute of Allergy and Infectious Diseases (NIAID) have agreed to share technical expertise related to the development of next-generation messenger RNA (mRNA) vaccines and therapeutics. . Site visits are planned, with Afrigen expected to visit the VRC in Maryland, US, later this year. .

Manufacturing 74

Manufacturing Medicine Management Pharmaceutical 74

Pharmaceutical Technology

JUNE 20, 2023

The University of Melbourne and Australia’s Victoria state government have unveiled the building design and location for the new A$650m Australian Institute for Infectious Disease (AIID). The AIID will provide quick responses to existing and future infectious diseases and pandemics for Australians.

Government 52

Government Leads 52

European Pharmaceutical Review

DECEMBER 5, 2023

The promise of telomerase inhibitors for treating blood cancer Trial results The clinical trial enrolled a total of 178 patients. Significant and clinically meaningful efficacy results were achieved across key MDS subgroups irrespective of ring sideroblast (RS) status, baseline transfusion burden and IPSS risk category.

Food and Drug Administration 98

Food and Drug Administration Patients Food Medicine 98

Pharmaceutical Technology

MARCH 21, 2023

Pre-clinical-stage biotechnology firm InvisiShield Technologies has partnered with Gladstone Institutes to develop intranasal preventatives against airborne viral infections including influenza, respiratory syncytial virus (RSV) and SARS-CoV-2.

Safety 115

Safety Medical Patients 115

Pharmaceutical Technology

JUNE 7, 2023

The US Food and Drug Administration (FDA) has granted approval for a new indication for Merck’s PREVYMIS (letermovir) to prevent cytomegalovirus (CMV) disease in high-risk adult kidney transplant recipients. We are delighted that PREVYMIS is now approved to help prevent CMV disease in adult kidney transplant patients at high risk. “We

Food and Drug Administration 52

Food and Drug Administration FDA Food Medicine 52

Pharmaceutical Technology

MAY 31, 2023

ZNA-1041 is under clinical development by F. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases.

Medicine 52

Medicine Healthcare Healthcare Management 52

European Pharmaceutical Review

OCTOBER 18, 2022

Over the next five years research at the National Institute for Health Research (NIHR) Sheffield Biomedical Research Centre (BRC) will include vaccine development for infectious diseases, funded in part by a £12 million grant from the National Institute for Health Research (NIHR).

Engineering 78

Engineering Doctors Patients Pharmaceutical 78

Pharmaceutical Technology

JULY 21, 2022

The latest deal is the second with AstraZeneca to reserve the treatment that can be given to patients having Covid-19 symptoms and are at increased risk of progression to severe disease. According to data from the PROVENT clinical trial, AZD7442 demonstrated a statistically significant decline in symptomatic Covid-19 development risk.

Government 105

Government Patients Medical Pharmaceutical 105

Pharmaceutical Technology

SEPTEMBER 16, 2022

The latest conditional recommendation is based on the final data from the SOLIDARITY clinical trial, which was sponsored by the WHO. These results are in line with those obtained from the placebo-controlled, double-blind ACTT-1 trial of the National Institute of Allergy and Infectious Diseases.

Food and Drug Administration 110

Food and Drug Administration Food Patients Medical 110

European Pharmaceutical Review

AUGUST 17, 2023

NIH’s vaccine candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials, produced in an A549 cell line. MHRA authorises new COVID-19 vaccine What will the intranasal vaccine manufacturing project involve?

Manufacturing 89

Manufacturing Medicine Physicians Safety 89

Pharmaceutical Technology

MAY 12, 2023

The division of infectious diseases at Weill Cornell Medicine carried out the work in collaboration with JAFRAL and JMI Laboratories. The US Food and Drug Administration has granted fast-track designation to SNIPR001, which is currently in clinical development.

Food and Drug Administration 98

Food and Drug Administration Engineering Food Medicine 98

Pharmaceutical Technology

NOVEMBER 21, 2022

This will aid in the production of new raw materials and possible clinical-grade assets to develop mRNA vaccines and therapies for infectious diseases, as well as other ailments with unmet needs. RVAC is currently developing mRNA-based vaccines against infectious diseases such as Covid-19.

Medicine 52

Medicine Manufacturing Pharmaceutical Leads 52

pharmaphorum

JULY 12, 2022

Researchers in the US have started a clinical trial of a vaccine against Nipah virus, a serious infection caught from animals that has a fatality rate of between 40% and 70%, developed by mRNA specialist Moderna. “The need for a preventive Nipah virus vaccine is significant,” he added.

Safety 52

Safety Leads 52

European Pharmaceutical Review

JULY 13, 2022

The US National Institute of Allergy and Infectious Diseases (NIAID) has launched a Phase I clinical trial to evaluate a messenger RNA (mRNA) vaccine developed to prevent infection with Nipah virus. Nipah virus infection is a zoonotic disease (ie, it spreads between animals and people) and fruit bats are its natural host.

Safety 82

Safety Manufacturing Leads Pharmaceutical 82

Pharmaceutical Technology

FEBRUARY 25, 2023

ASP-1570 is under clinical development by Astellas Pharma and currently in Phase II for Metastatic Melanoma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pharma 52

Pharma Networking Manufacturing Pharmaceutical 52

Pharmaceutical Technology

FEBRUARY 25, 2023

ASP-1570 is under clinical development by Astellas Pharma and currently in Phase II for Solid Tumor. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pharma 52

Pharma Networking Manufacturing Pharmaceutical 52

Legacy MEDSearch

JANUARY 3, 2023

Both the CDC and the Infectious Disease Society of America recommend clinicians should use rapid molecular assays (i.e., He further added, “Use of the Visby Respiratory Health Test at the point of care in urgent care clinics and emergency rooms will transform how patients with respiratory symptoms are diagnosed and treated.”

Medical 98

Medical Food and Drug Administration FDA Recruitment 98

Pharmaceutical Technology

OCTOBER 6, 2022

from the US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) to develop a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). A sexually transmitted disease, gonorrhoea is caused by the NG bacteria. Intravacc has received a contract worth $14.6m

Manufacturing 59

Manufacturing Safety Pharmaceutical 59

Pharmaceutical Technology

JUNE 8, 2023

Publication of these results in Nature Communications supports the scientific rigor of our work and potential clinical utility of our next-generation vaccine platform for the prevention of infectious diseases, including coronaviruses, such as Covid-19,” said Andrew Allen, Chief Executive Officer of Gritstone.

Safety 52

Safety Management 52

PM360

MARCH 27, 2024

Clinical development projects have grown from just a few dozen before the pandemic to 1,503 programs today, according to clinicaltrials.gov. A Bright Future for mRNA Therapeutics mRNA is currently one of the most versatile ways to address both infectious and noninfectious diseases.

Manufacturing 52

Manufacturing Marketing Patients 52

European Pharmaceutical Review

SEPTEMBER 15, 2023

Recent clinical trial news for Janssen’s RYBREVANT J&J Innovative Medicine covers the following therapeutic areas: cardiovascular, metabolism & retina, immunology, infectious diseases, neuroscience, oncology, as well as pulmonary hypertension.

Medicine 93

Medicine Pharmaceutical Safety Medical 93

Pharmaceutical Technology

FEBRUARY 25, 2023

ASP-1570 is under clinical development by Astellas Pharma and currently in Phase II for Non-Small Cell Lung Carcinoma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pharma 52

Pharma Networking Pharmaceutical Manufacturing 52